The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA) -approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage.

In accordance with the Accreditation Council for Continuing Medical Education's Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.

Planning Committee and Faculty members report the following relationship(s):

Author(s)

Mark R. Gilbert, MD, Course Chair

Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Disclosures

Disclosure: Consulting Fees: Genentech, Merck & Co, Abbott.

Kenneth D. Aldape, MD

Associate Professor, Department of Pathology, M.D. Anderson Cancer Center, Houston, Texas

Disclosures

Disclosure: No relevant financial relationships to disclose.

Terri S. Armstrong, PhD, MS, APRN, BS

Associate Professor and John S. Dunn Distinguished Professor in Oncology Nursing, UTHSC-SON, Adjunct Associate Professor, Department of Neuro-Oncology, M.D. Anderson Cancer Center, Houston, Texas

Disclosures

Disclosure: No relevant financial relationships to disclose.

Minesh P. Mehta, MD

Professor, Radiation Oncology, Northwestern University, Feinberg School of Medicine

Disclosures

Disclosure: Receipt of Intellectual property rights/patent holder: Procertus; Consulting Fees: Merck & Co; Fees for Non-CME services received directly from commercial agents or their agents: Pharmacyclics; Ownership Interest: Tomotherapy; Pharmacyclics.

External reviewer reports the following relationship(s):

Roger Stupp, MD

Disclosures

Disclosure: Advisory Boards: Actelion, Roche, MSD (Merck & co), Merck Serono (EMD).

Vindico and HEMONC TODAY^® staff report the following relationship(s):
No relevant financial relationships to disclose.

Scheduled speakers for Glioblastoma: Current Perspectives, Clinical Challenges, and Trends in Treatment, have provided the above disclosure information, which is accurate at the time of release of this activity.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

CME

Glioblastoma: Current Perspectives, Clinical Challenges, and Trends in Treatment

Authors: Mark R. Gilbert, MD, Course Chair; Kenneth D. Aldape, MD; Terri S. Armstrong, PhD, MS, APRN, BS; Minesh P. Mehta, MD
CME Released: 8/17/2011
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 8/17/2012, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity was developed for medical oncologists, surgical oncologists, hematologists/oncologists, oncology nurses, and other healthcare professionals involved in the treatment of patients with glioblastoma.

Glioblastoma (GBM), the most common primary malignant brain tumor, historically has had an overall poor prognosis, despite surgical resection and external beam radiotherapy. The addition of temozolomide chemotherapy, both concurrent with radiation and as additional adjuvant treatment, improved overall survival. Methylguanine methyltransferase (MGMT) activity may impact response to temozolomide, and increasing dose intensity has been postulated to improve response in both MGMT-expressing (MGMT promoter unmethylated) and MGMT non-expressing (MGMT promoter methylated) tumors. This CME video highlights the findings from the recently released RTOG 0525 clinical trial, which compared the efficacy of standard vs. intensified dosing of temozolomide in the treatment of GBM. In addition, RTOG 0525 explored patient-reported outcomes (neurocognitive testing, quality of life metrics, and patient symptoms/toxicity). Study participants outline those key findings. Finally, faculty discuss the impact of molecular testing of tumor samples and its role in patient stratification for optimal therapy and improved prognosis.

Upon completion of this activity, participants should be able to:

Understand the use of temozolomide (its drug category) in the management of newly diagnosed glioblastoma.
Apply findings of the investigative RTOG 0525 clinical trial to neuro-oncology clinical practice.
Explain the longitudinal impact of combination chemotherapy/radiation therapy on newly diagnosed glioblastoma patients.
Describe the applicability of molecular studies in glioblastoma case management.

Disclosures

Planning Committee and Faculty members report the following relationship(s):

Author(s)

Mark R. Gilbert, MD, Course Chair

Professor, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, Texas

Disclosures

Disclosure: Consulting Fees: Genentech, Merck & Co, Abbott.

Kenneth D. Aldape, MD

Associate Professor, Department of Pathology, M.D. Anderson Cancer Center, Houston, Texas

Disclosures

Disclosure: No relevant financial relationships to disclose.

Terri S. Armstrong, PhD, MS, APRN, BS

Associate Professor and John S. Dunn Distinguished Professor in Oncology Nursing, UTHSC-SON, Adjunct Associate Professor, Department of Neuro-Oncology, M.D. Anderson Cancer Center, Houston, Texas

Disclosures

Disclosure: No relevant financial relationships to disclose.

Minesh P. Mehta, MD

Professor, Radiation Oncology, Northwestern University, Feinberg School of Medicine

Disclosures

Disclosure: Receipt of Intellectual property rights/patent holder: Procertus; Consulting Fees: Merck & Co; Fees for Non-CME services received directly from commercial agents or their agents: Pharmacyclics; Ownership Interest: Tomotherapy; Pharmacyclics.

External reviewer reports the following relationship(s):

Roger Stupp, MD

Disclosures

Disclosure: Advisory Boards: Actelion, Roche, MSD (Merck & co), Merck Serono (EMD).

Accreditation Statements

For Physicians

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Vindico Medical Education and HEMONC TODAY®. Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For the purpose of recertifying with American Nurses Credentialing Center, AMA PRA Category 1 CME Credits™ from organizations accredited by ACCME can be used.

This enduring material is approved for 1 year from the date of original release.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. In addition, you must complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CME

Glioblastoma: Current Perspectives, Clinical Challenges, and Trends in Treatment

Authors: Mark R. Gilbert, MD, Course Chair; Kenneth D. Aldape, MD; Terri S. Armstrong, PhD, MS, APRN, BS; Minesh P. Mehta, MDFaculty and Disclosures

THIS ACTIVITY HAS EXPIRED FOR CREDIT

CME Released: 8/17/2011

Valid for credit through: 8/17/2012, 11:59 PM EST

processing....

Download Audio

This CME activity was developed to be distributed on Medscape, HEMONC TODAY^® Education Lab and developed into a CME monograph that will mail in the October issue of HEMONC TODAY^®.

This feature requires the newest version of Flash. You can download it here.

CME Information

Print
Like Tweet

Disclaimer

The material presented here does not necessarily reflect the views of Medscape, LLC, or companies that support educational programming on www.medscape.org. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

© 2011 Created and published by Vindico Medical Education 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Copyright© 2011 Slack Incorporated^®. All rights reserved. No part of this activity may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and HEMONC TODAY^® continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and HEMONC TODAY^®. Neither Vindico Medical Education, HEMONC TODAY^®, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the United States Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

Faculty and Disclosures

Author(s)

Mark R. Gilbert, MD, Course Chair

Kenneth D. Aldape, MD

Terri S. Armstrong, PhD, MS, APRN, BS

Minesh P. Mehta, MD

Roger Stupp, MD

CME

Glioblastoma: Current Perspectives, Clinical Challenges, and Trends in Treatment

Target Audience and Goal Statement

Disclosures

Author(s)

Mark R. Gilbert, MD, Course Chair

Kenneth D. Aldape, MD

Terri S. Armstrong, PhD, MS, APRN, BS

Minesh P. Mehta, MD

Roger Stupp, MD

Accreditation Statements

For Physicians

Instructions for Participation and Credit

Glioblastoma: Current Perspectives, Clinical Challenges, and Trends in Treatment